Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H Sehn, MD, David W. Scott, MBChB, PhD, Diego Villa, MD FRCPC, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Pedro Farinha, MD PhD, Graham W Slack, MD PhD, Don Wilson, MD, R. Petter Tonseth, MD, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 401.

https://doi.org/10.1182/blood-2019-128722

Published: 2019

Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 6.

https://doi.org/10.1182/blood-2019-123742

Published: 2019

Journal Articles

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Blood (2019) 134 (Supplement_1): 1524.

https://doi.org/10.1182/blood-2019-129024

Published: 2019

Journal Articles

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Phoebe Tsz Man Cheng, BSc,MD, Diego Villa, MD MPH, R. Petter Tonseth, MD, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Don Wilson, MD, Brian Skinnider, MD, Laurie H Sehn, MD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 2845.

https://doi.org/10.1182/blood-2019-122019

Published: 2019

Journal Articles

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Diego Villa, MD MPH, Laurie H Sehn, MD, Kerry J Savage, BSc, MD MSc, Cynthia L Toze, MD FRCPC, Kevin Song, MD, Wendie L den Brok, Ciara L Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 2814.

https://doi.org/10.1182/blood-2019-124217

Published: 2019

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 489.

https://doi.org/10.1182/blood-2019-123626

Published: 2019

Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD

Blood (2019) 134 (Supplement_1): 1285.

https://doi.org/10.1182/blood-2019-123961

Published: 2019

Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 354.

https://doi.org/10.1182/blood-2019-124443

Published: 2019

Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 4081.

https://doi.org/10.1182/blood-2019-123449

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD

Blood (2019) 134 (Supplement_1): 883.

https://doi.org/10.1182/blood-2019-123450

Published: 2019

Journal Articles

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Anjali Silva, PhD MSc, BSc, Clementine Sarkozy, MD, Tracy Lackraj, PhD BSc, Anja Mottok, Vindi Jurinovic, MSc, Laurie H Sehn, MD MPH, Oliver Weigert, MD, Christian Steidl, MD, Robert Kridel, PhD MD

Blood (2018) 132 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2018-99-112689

Published: 2018

Journal Articles

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Blood (2018) 132 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2018-99-116750

Published: 2018

Journal Articles

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Hatem Alahwal, MPH, MBBS, Parv Chapani, Diego Villa, MD FRCPC, Yasser Abou Mourad, MD, Maryse Power, MD, Stephen H. Nantel, MD, David Sanford, MD, Gayatri Sreenivasan, BSc, MD, Heather J. Sutherland, MD PhD, Laurie H Sehn, MD MPH, Cynthia L. Toze, MD FRCPC, MSc, Raewyn Broady, MBChB, Kevin Song, MD, Paul Yenson, MD BSc, FRCPC, Alina S. Gerrie, MD MPH

Blood (2018) 132 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2018-99-114371

Published: 2018

Journal Articles

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2018-99-112010

Published: 2018

Journal Articles

Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma

Anna R Hayden, MD, Derrick G Lee, PhD, Diego Villa, MD, Alina S. Gerrie, MD MPH, David W. Scott, PhDMD, FRACP, FRCPA, Graham W Slack, MD, Laurie H Sehn, MD MPH, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2018) 132 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2018-99-111047

Published: 2018

NARROW

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only